Ticker tape by TradingView

July 17, 2020

Aptose Biosciences To Go Through With Public Offering, What This Could Do for the Stock

Frank Cabibi

On July 16th, Aptose or NASDAQ: APTO announced that they will have a public offering of 10.5 million shares at $5.25 per on July 20th.

What does this mean?

Basically, a company will sell shares of their own stock to raise capital in a public offering. This is usually something small-caps go through with if they are not making money or need more capital for operations. In APTO's case, they are running out of cash, and this isn't the first time they've done a public offering. Seeking Alpha mentions that approximately $55 million to be raised in the offering.

What is Aptose Biosciences?

ATPO is a clinical-stage biotech that works in the field of oncology, or treating tumors. Looking at the past 4 years, they have not made a profit like most biotechs because of the amount of spending each company has to undertake in their clinical-trial stages.

https://finance.yahoo.com/quote/APTO/cash-flow?p=APTO

Their cash flow looks like the source of their problems. Financing cash flow left at $436,000 in March with all other areas negative except end cash position. The fact that the company is undergoing another public offer must mean that they still haven't gathered enough cash or need a lot more. $55 million should help pad expenses for their CG-806 and APTO-253 clinical trials next quarter or maybe further down the road.

What I think

Since the offering is at $5.25 per share, it's expected to see the price drop. However, there is something I looked at that could be a good sign for Aptose.

https://www.marketbeat.com/stocks/NASDAQ/APTO/institutional-ownership/

Almost 40% of the stock is owned by institutions, and Q2 saw a lot of increases of institutional stakes betting on this company. A good thing about institutional ownership is that it can limit price volatility since it's unlikely smart money will decide to buy up shares and dump it all the next quarter. $22 million bought by institutions also shows investor interest which could mean APTO is getting close to a clinical breakthrough. But that is pure speculation that I made so take that with a grain of salt.

Technicals

The stock looks like it's just about oversold on the 14-Day RSI chart, and price dips under the 200 Day Moving Average after trading above it since November of last year. Patterns on the RSI show that the stock could be gearing for another swing to the upside. If APTO's RSI slides under 30, it could be something to consider buying. On Marketbeat, analysts give this stock a buy rating with an $11.40 Price Target the past two quarters.

https://www.marketbeat.com/stocks/NASDAQ/APTO/price-target/

Featured Pic: https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/5491524/5491524-1589481251193-a23bd02f95f7c.jpg


Thanks for reading! If you are interested in joining our trading community, we have chat rooms, trade alerts from our top traders, and educational content. You can join using the link below, and get a discount on your membership.

Disclaimer:

Please note that this email is my personal opinion only. I am not a licensed financial advisor, and any information shared or discussed is not to be construed as investment advice. Trading and investing involves a degree of risk, and is not suitable to all investors. Please consult with your financial advisor before making any sort of investment decisions.

A1 Edgefinder

FLASH SALE
Take 40% off the Edge finder using code "READER"
GET ACCESS NOW

want to see what we're trading?

Join The VIP Community!
Our entries, exits & analysis
Live Webinar Coaching
Trading Chatrooms
Strategy Library 
Exclusive Trading Guides
Use Code "READER" for 10% OFF!
JOIN NOWJoin FREE Discord
A1 Trading Podcast
We Like These Pairs For Next Week

As this week comes to a close, we are looking ahead at future setups that could be some of the best opportunities for the next several trading sessions. Here are some pairs for next week that we are looking at. EUR/JPY Recent data has shown a slow down in the German manufacturing sector. With European […]

Read More
More Downside On The SPX500 After This?

When it comes to testimonies, it's all in how you say it. Jerome Powell has to be very particular in the way he makes his statements and answers the ensuing questions. Here is what might be in store for the market in the coming days and weeks, and whether or not there will be more […]

Read More
More Upside For Yen After This

The historically 'safe' currency to hold in times of recessions is in a unique situation now with a couple factors in place. Here is why the yen is stronger today as well as some trade setups that could push its value either up or down. Weaker Yen Now, Stronger Yen Later The Bank of Japan […]

Read More
DISCLAIMER: All comments made by TraderNick’s Forex Group, LLC are for educational and informational purposes only. All comments should not be construed as investment advice regarding the purchase or sale of any securities or financial instrument of any kind. Please consult with your financial adviser before making an investment decision regarding any securities or financial instruments mentioned by TraderNick’s Forex Group, LLC. TraderNick’s Forex Group, LLC assumes no responsibility for your trading and investment results. All information on any of the platforms utilized by TraderNick’s Forex Group, LLC was obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. TraderNick’s Forex Group, LLC, its employees, representatives, and affiliated individuals may have a position or effect transactions in the securities and financial instruments herein and or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies. Trading of any type involves very high risk and may not be suitable for all investors. TraderNick’s Forex Group, LLC, its subsidiaries and all affiliated individuals assume no responsibility for your trading and investment result. Read our full disclaimer here
homescreensmartphone linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram